Notice of a Limited Partner Investment Agreement with LSP Dementia Fund

OSAKA, Japan, March 29, 2023 - Shionogi & Co., Ltd.  (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that Shionogi has concluded a Limited Partner investment agreement ("this agreement") with LSP Dementia Fund (Administrative office:Netherlands, Head: Philip Scheltens, M.D., Ph.D.; hereafter "LSP DF")


LSP DF is a fund managed by EQT Life Sciences, one of Europe's largest investment firms providing financing to life sciences and healthcare companies. LSP DF primarily invests in companies developing pharmaceuticals and medical devices, with a focus on neurodegenerative diseases and dementia. Professor Philip Scheltens, a world-renowned Dutch dementia researcher is the representative, and LSP DF also have a network of KOLs and experts with extensive non-clinical/clinical experience in the central nervous system area.


In this agreement, Shionogi will be able to utilize the network of LSP DF, and will be able to gain a deep understanding of companies that are investment candidates for LSP DF. In connection with this, Shionogi expects to expand its network of collaborative and advisory relationships in the cognition area and in allied fields, leading to the enhancement of its research activities and to pipeline expansion, with broader and stronger connections throughout the CNS-related innovation ecosystem. As a Limited Partner, Shionogi will capital contributions to LSP DF, and in return, we will receive a distribution of the gains from the fund, in accordance with the investment ratio.


Shionogi is committed to “Improve social productivity and extend healthy lifespan” as our key focus. We are working to achieve a global society characterized by healthy longevity, in which all can enjoy more rewarding lives. We will continue to progress our research and development activities, with ever greater use of external networks so that we can develop and provide healthcare products and services for central nervous system diseases, which have a major impact on healthy life expectancy.



【About EQT Life Sciences】

EQT Life Sciences was formed in 2022 following the integration of LSP, a leading European life sciences venture capital firm, into the EQT platform. As LSP, the firm raised over EUR 3.0 billion (USD 3.5 billion) and supported the growth of more than 150 companies since it started to invest over 30 years ago.

For more information, please visit https://www.lspvc.com/index.html


【About Limited Partner investment】

Venture funds consist of a general partner (GP) who manages the operation of the fund and limited partners (LP) who invest in the fund. Under this agreement, LSP DF will be the GP and Shionogi will be an LP.


For Further Information, Contact:

SHIONOGI Website Inquiry Form : https://www.shionogi.com/global/en/contact.html